Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)
Moderna Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months) increased by 800.0% to $9.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 350.0%, from $2.00M to $9.00M. Over 4 years (FY 2021 to FY 2025), Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months) shows a downward trend with a -62.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase suggests short-term market headwinds or rising interest rates affecting the portfolio's market value.
Detailed definition
This metric tracks the unrealized losses on available-for-sale debt securities that have been in a loss position for les...
Peer comparison
Standard disclosure for financial reporting under GAAP to assess investment portfolio health.
afs_debt_securities_unrealized_loss_less_than_12mHistorical Data
| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $52.00M | $271.00M | $357.00M | $373.00M | $241.00M | $59.00M | $46.00M | $14.00M | $4.00M | $11.00M | $9.00M | $1.00M | $6.00M | $2.00M | $2.00M | $0.00 | $1.00M | $9.00M |
| QoQ Change | — | +421.2% | +31.7% | +4.5% | -35.4% | -75.5% | -22.0% | -69.6% | -71.4% | +175.0% | -18.2% | -88.9% | +500.0% | -66.7% | +0.0% | -100.0% | — | +800.0% |
| YoY Change | — | — | — | — | +363.5% | -78.2% | -87.1% | -96.2% | -98.3% | -81.4% | -80.4% | -92.9% | +50.0% | -81.8% | -77.8% | -100.0% | -83.3% | +350.0% |
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months) at Other Companies
Frequently Asked Questions
- What is Moderna's available-for-sale debt securities - unrealized loss position (<12 months)?
- Moderna (MRNA) reported available-for-sale debt securities - unrealized loss position (<12 months) of $9.00M in Q1 2026.
- How has Moderna's available-for-sale debt securities - unrealized loss position (<12 months) changed year-over-year?
- Moderna's available-for-sale debt securities - unrealized loss position (<12 months) increased by 350.0% year-over-year, from $2.00M to $9.00M.
- What is the long-term trend for Moderna's available-for-sale debt securities - unrealized loss position (<12 months)?
- Over 4 years (2021 to 2025), Moderna's available-for-sale debt securities - unrealized loss position (<12 months) has grown at a -62.8% compound annual growth rate (CAGR), from $52.00M to $1.00M.
- What does available-for-sale debt securities - unrealized loss position (<12 months) mean?
- The value of investments currently worth less than their cost, held for less than a year.